Clinical Trials for Pancreas Cancer

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors harboring a KRAS mutation or high-level KRAS wild-type amplification receive the investigational oral pan-KRAS inhibitor BGB-53038 alone or with tislelizumab (anti–PD-1) for nonsquamous NSCLC or cetuximab (anti-EGFR) for colorectal cancer. The study has been terminated, in part because of a lack of promising efficacy.

ClinicalTrials.gov ID: NCT06585488

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced or metastatic KRAS G12D-mutated solid tumors, including pancreatic, colorectal, and non-small cell lung cancers, receive the oral KRAS G12D inhibitor INCB161734 alone or with cetuximab, retifanlimab, gemcitabine/nab-paclitaxel, or modified FOLFIRINOX. Prior KRAS G12D inhibitor treatment is excluded.

ClinicalTrials.gov ID: NCT06179160

A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic KRAS-mutant solid tumors who have progressed on, cannot tolerate, or declined appropriate standard therapy receive oral ALTA3263. This investigational KRAS isoform-selective inhibitor is designed to bind mutant KRAS in both active and inactive states, including G12V, G12D, and G12C.

ClinicalTrials.gov ID: NCT06835569

A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced KRAS-mutated solid tumors and ECOG 0–1, including PDAC, CRC, and NSCLC, receive oral PF-07934040, an investigational pan-KRAS inhibitor, either alone in later-line cohorts or with standard agents in tumor-specific cohorts. First-line combinations include gemcitabine/nab-paclitaxel for PDAC, FOLFOX/bevacizumab for CRC, and pembrolizumab with or without platinum chemotherapy for NSCLC; later-line CRC may receive PF-07934040 plus cetuximab.

ClinicalTrials.gov ID: NCT06447662

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants with KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with KRAS G12C-mutated locally advanced unresectable or metastatic solid tumors who have progressed on or cannot receive standard therapy receive oral FMC-376, an investigational inhibitor designed to covalently target both active and inactive KRAS G12C.

ClinicalTrials.gov ID: NCT06244771

An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA-C*08:02-positive, KRAS G12D-mutant unresectable advanced or metastatic solid tumors who have received at least one approved systemic regimen and have no curative option receive a single infusion of NT-112, an autologous TCR-engineered T-cell therapy targeting KRAS G12D presented by HLA-C*08:02. Treatment includes lymphodepletion before infusion and a short course of interleukin-2 afterward.

ClinicalTrials.gov ID: NCT06218914

An Open-label Phase 1 Study to Investigate SGN-CEACAM5C in Adults With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed, refractory, or progressive unresectable or metastatic solid tumors, including colorectal, gastric/gastroesophageal junction, pancreatic, and lung cancers, receive PF-08046050, a CEACAM5-targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor. Previously treated colorectal adenocarcinoma cohorts receive PF-08046050 with bevacizumab.

ClinicalTrials.gov ID: NCT06131840

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic solid tumors, measurable disease, and ECOG performance status 0–1 receive intravenous MDX2001 monotherapy. MDX2001 is an investigational tetraspecific antibody that binds c-MET and TROP2 on tumors while engaging CD3 and providing CD28 costimulation to promote tumor-directed T-cell activity.

ClinicalTrials.gov ID: NCT06239194

A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or recurrent solid tumors that have progressed after prior treatment and lack suitable standard options receive [225Ac]-FPI-2068, an investigational EGFR/c-MET-targeted alpha-emitting radioimmunotherapy. A nonradioactive FPI-2053 antibody predose is used to optimize biodistribution, with [111In]-FPI-2107 SPECT imaging used to assess uptake and dosimetry.

ClinicalTrials.gov ID: NCT06147037

A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with measurable, unresectable or metastatic KRAS G12D-mutant solid tumors, ECOG 0–1, and at least one prior systemic chemotherapy regimen receive oral debecarasib (LY3962673), a mutant-selective inhibitor of GDP-bound KRAS G12D. Treatment is given alone or with cetuximab or chemotherapy agents.

ClinicalTrials.gov ID: NCT06586515